オプションチェーンは、Cielo SA ADRの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Cielo SA ADRの市場センチメントを評価します。.

Cielo SA ADR (OTC:CIOXY) 株価情報, オプションチェーン

Cielo

CIELO SA

Cielo SA ADR

Cielo (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CIOXY#OTC">CIOXY</a>) reported quarterly earnings of $0.04 per share. This is a 100 percent increase over earnings of $0.02 per share from the same period last year. The company reported $559.26 million in sales this quarter. This is a 6.84 percent increase over sales of $523.46 million the same period last year.

Earnings

News

CIOXY

Cielo Q4 EPS $0.04 Up From $0.02 YoY, Sales $559.26M Up From $523.46M YoY

&nbsp;
<h2>Upgrades</h2>
<ul>
<li>For Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>), Benchmark upgraded the previous rating of Hold to Buy. Nektar Therapeutics earned $0.70 in the third quarter, compared to $0.61 in the year-ago quarter. The stock has a 52-week-high of $26.75 and a 52-week-low of $12.35. At the end of the last trading period, Nektar Therapeutics closed at $13.45.</li>
<li>Needham upgraded the previous rating for Cognex Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) from Hold to Buy. Cognex earned $0.40 in the third quarter, compared to $0.47 in the year-ago quarter. The stock has a 52-week-high of $101.82 and a 52-week-low of $69.06. At the end of the last trading period, Cognex closed at $78.96.</li>
<li>For Interface Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TILE#NASDAQ">TILE</a>), Raymond James upgraded the previous rating of Market Perform to Outperform. Interface earned $0.29 in the third quarter, compared to $0.28 in the year-ago quarter. At the moment, the stock has a 52-week-high of $17.11 and a 52-week-low of $6.50. Interface closed at $15.99 at the end of the last trading period.</li>
<li>According to Deutsche Bank, the prior rating for Accel Entertainment Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACEL#NYSE">ACEL</a>) was changed from Hold to Buy. In the third quarter, Accel Entertainment showed an EPS of $0.18, compared to $0.16 from the year-ago quarter. The stock has a 52-week-high of $13.75 and a 52-week-low of $8.82. At the end of the last trading period, Accel Entertainment closed at $13.18.</li>
<li>According to Truist Securities, the prior rating for Appian Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPN#NASDAQ">APPN</a>) was changed from Hold to Buy. In the third quarter, Appian showed an EPS of $0.22, compared to $0.00 from the year-ago quarter. The stock has a 52-week-high of $260.00 and a 52-week-low of $72.00. At the end of the last trading period, Appian closed at $90.73.</li>
<li>For KVH Industries Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KVHI#NASDAQ">KVHI</a>), Raymond James upgraded the previous rating of Outperform to Strong Buy. KVH Industries earned $0.05 in the third quarter, compared to $0.06 in the year-ago quarter. The stock has a 52-week-high of $15.29 and a 52-week-low of $8.52. At the end of the last trading period, KVH Industries closed at $10.49.</li>
<li>Morgan Stanley upgraded the previous rating for AvalonBay Communities Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVB#NYSE">AVB</a>) from Equal-Weight to Overweight. AvalonBay Communities earned $2.06 in the third quarter, compared to $2.06 in the year-ago quarter. The stock has a 52-week-high of $241.63 and a 52-week-low of $146.95. At the end of the last trading period, AvalonBay Communities closed at $237.84.</li>
<li>According to Benchmark, the prior rating for ACM Research Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACMR#NASDAQ">ACMR</a>) was changed from Hold to Buy. ACM Research earned $0.56 in the third quarter, compared to $0.42 in the year-ago quarter. The current stock performance of ACM Research shows a 52-week-high of $144.81 and a 52-week-low of $60.84. Moreover, at the end of the last trading period, the closing price was at $102.69.</li>
<li>According to Jefferies, the prior rating for Fair Isaac Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>) was changed from Hold to Buy. Fair Isaac earned $3.38 in the third quarter, compared to $2.58 in the year-ago quarter. The current stock performance of Fair Isaac shows a 52-week-high of $553.97 and a 52-week-low of $379.41. Moreover, at the end of the last trading period, the closing price was at $380.20.</li>
<li>For Tenaris SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TS#NYSE">TS</a>), JP Morgan upgraded the previous rating of Neutral to Overweight. In the third quarter, Tenaris showed an EPS of $0.56, compared to $0.06 from the year-ago quarter. The stock has a 52-week-high of $24.78 and a 52-week-low of $11.77. At the end of the last trading period, Tenaris closed at $24.71.</li>
<li>BTIG upgraded the previous rating for AG Mortgage Investment Trust Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MITT#NYSE">MITT</a>) from Sell to Neutral. For the third quarter, AG Mortgage Investment had an EPS of $0.96, compared to year-ago quarter EPS of $0.44. At the moment, the stock has a 52-week-high of $13.22 and a 52-week-low of $2.65. AG Mortgage Investment closed at $13.00 at the end of the last trading period.</li>
</ul>
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings upgrades.</a>
&nbsp;
<h2>Downgrades</h2>
<ul>
<li>For Deciphera Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCPH#NASDAQ">DCPH</a>), Truist Securities downgraded the previous rating of Buy to Hold. For the third quarter, Deciphera Pharmaceuticals had an EPS of $1.37, compared to year-ago quarter EPS of $1.13. At the moment, the stock has a 52-week-high of $68.40 and a 52-week-low of $8.70. Deciphera Pharmaceuticals closed at $8.82 at the end of the last trading period.</li>
<li>For bluebird bio Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>), Goldman Sachs downgraded the previous rating of Neutral to Sell. In the third quarter, bluebird bio showed an EPS of $3.16, compared to $2.94 from the year-ago quarter. The stock has a 52-week-high of $53.68 and a 52-week-low of $12.90. At the end of the last trading period, bluebird bio closed at $13.14.</li>
<li>Argus Research downgraded the previous rating for Harsco Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSC#NYSE">HSC</a>) from Buy to Hold. For the third quarter, Harsco had an EPS of $0.20, compared to year-ago quarter EPS of $0.08. At the moment, the stock has a 52-week-high of $23.73 and a 52-week-low of $12.65. Harsco closed at $15.43 at the end of the last trading period.</li>
<li>Northcoast Research downgraded the previous rating for Shake Shack Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>) from Buy to Neutral. For the third quarter, Shake Shack had an EPS of $0.05, compared to year-ago quarter EPS of $0.11. The stock has a 52-week-high of $138.38 and a 52-week-low of $68.23. At the end of the last trading period, Shake Shack closed at $90.97.</li>
<li>For McAfee Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCFE#NASDAQ">MCFE</a>), Deutsche Bank downgraded the previous rating of Buy to Hold. Interestingly, in the second quarter, McAfee&#39;s EPS was $0.28. The stock has a 52-week-high of $32.83 and a 52-week-low of $14.80. At the end of the last trading period, McAfee closed at $25.46.</li>
<li>B of A Securities downgraded the previous rating for Purple Innovation Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPL#NASDAQ">PRPL</a>) from Buy to Underperform. In the second quarter, Purple Innovation showed an EPS of $0.05, compared to $0.11 from the year-ago quarter. The current stock performance of Purple Innovation shows a 52-week-high of $41.08 and a 52-week-low of $18.50. Moreover, at the end of the last trading period, the closing price was at $19.50.</li>
<li>B of A Securities downgraded the previous rating for Spire Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SR#NYSE">SR</a>) from Buy to Neutral. In the third quarter, Spire showed an EPS of $0.06, compared to $0.07 from the year-ago quarter. The current stock performance of Spire shows a 52-week-high of $77.95 and a 52-week-low of $57.11. Moreover, at the end of the last trading period, the closing price was at $63.35.</li>
<li>According to Piper Sandler, the prior rating for Itron Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRI#NASDAQ">ITRI</a>) was changed from Overweight to Neutral. For the third quarter, Itron had an EPS of $0.21, compared to year-ago quarter EPS of $0.61. At the moment, the stock has a 52-week-high of $122.31 and a 52-week-low of $66.32. Itron closed at $79.12 at the end of the last trading period.</li>
<li>Morgan Stanley downgraded the previous rating for UDR Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UDR#NYSE">UDR</a>) from Overweight to Equal-Weight. In the third quarter, UDR showed an EPS of $0.51, compared to $0.50 from the year-ago quarter. The current stock performance of UDR shows a 52-week-high of $56.45 and a 52-week-low of $33.40. Moreover, at the end of the last trading period, the closing price was at $54.81.</li>
<li>According to Benchmark, the prior rating for Emergent BioSolutions Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) was changed from Buy to Hold. For the third quarter, Emergent BioSolutions had an EPS of $0.36, compared to year-ago quarter EPS of $2.19. The stock has a 52-week-high of $127.20 and a 52-week-low of $29.88. At the end of the last trading period, Emergent BioSolutions closed at $33.11.</li>
<li>According to Canaccord Genuity, the prior rating for Deciphera Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCPH#NASDAQ">DCPH</a>) was changed from Buy to Hold. For the third quarter, Deciphera Pharmaceuticals had an EPS of $1.37, compared to year-ago quarter EPS of $1.13. At the moment, the stock has a 52-week-high of $68.40 and a 52-week-low of $8.70. Deciphera Pharmaceuticals closed at $8.82 at the end of the last trading period.</li>
<li>Truist Securities downgraded the previous rating for Krispy Kreme Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNUT#NASDAQ">DNUT</a>) from Buy to Hold. In the second quarter, Krispy Kreme earned $0.13. The current stock performance of Krispy Kreme shows a 52-week-high of $21.69 and a 52-week-low of $12.63. Moreover, at the end of the last trading period, the closing price was at $14.10.</li>
<li>According to JMP Securities, the prior rating for Palomar Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLMR#NASDAQ">PLMR</a>) was changed from Market Outperform to Market Perform. In the third quarter, Palomar Hldgs showed an EPS of $0.07, compared to $0.60 from the year-ago quarter. The current stock performance of Palomar Hldgs shows a 52-week-high of $115.40 and a 52-week-low of $61.01. Moreover, at the end of the last trading period, the closing price was at $95.00.</li>
<li>For Calithera Biosciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALA#NASDAQ">CALA</a>), HC Wainwright &amp; Co. downgraded the previous rating of Buy to Neutral. Calithera Biosciences earned $0.19 in the second quarter, compared to $0.29 in the year-ago quarter. The current stock performance of Calithera Biosciences shows a 52-week-high of $6.18 and a 52-week-low of $0.83. Moreover, at the end of the last trading period, the closing price was at $0.86.</li>
<li>According to Stifel, the prior rating for Deciphera Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCPH#NASDAQ">DCPH</a>) was changed from Buy to Hold. Deciphera Pharmaceuticals earned $1.37 in the third quarter, compared to $1.13 in the year-ago quarter. The current stock performance of Deciphera Pharmaceuticals shows a 52-week-high of $68.40 and a 52-week-low of $8.70. Moreover, at the end of the last trading period, the closing price was at $8.82.</li>
<li>According to Piper Sandler, the prior rating for Aptiv PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) was changed from Overweight to Neutral. Aptiv earned $0.38 in the third quarter, compared to $1.13 in the year-ago quarter. At the moment, the stock has a 52-week-high of $180.81 and a 52-week-low of $101.14. Aptiv closed at $175.03 at the end of the last trading period.</li>
</ul>
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings downgrades.</a>
&nbsp;
<h2>Initiations</h2>
<ul>
<li>Maxim Group initiated coverage on Paltalk Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALT#NASDAQ">PALT</a>) with a Buy rating. The price target for Paltalk is set to $12.00. For the second quarter, Paltalk had an EPS of $0.12, compared to year-ago quarter EPS of $0.08. At the moment, the stock has a 52-week-high of $15.20 and a 52-week-low of $1.10. Paltalk closed at $4.52 at the end of the last trading period.</li>
<li>Jefferies initiated coverage on Walker &amp; Dunlop Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WD#NYSE">WD</a>) with a Buy rating. The price target for Walker &amp; Dunlop is set to $190.00. Walker &amp; Dunlop earned $2.21 in the third quarter, compared to $1.66 in the year-ago quarter. The stock has a 52-week-high of $147.87 and a 52-week-low of $65.79. At the end of the last trading period, Walker &amp; Dunlop closed at $145.49.</li>
<li>With a Buy rating, Benchmark initiated coverage on dMY Technology Group Inc IV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DMYQ#NYSE">DMYQ</a>). The price target seems to have been set at $17.00 for dMY Technology Group Inc. The stock has a 52-week-high of $10.48 and a 52-week-low of $9.57. At the end of the last trading period, dMY Technology Group Inc closed at $10.23.</li>
<li>Wedbush initiated coverage on 2seventy bio Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSVT#NASDAQ">TSVT</a>) with an Outperform rating. The price target for 2seventy bio is set to $40.00. At the end of the last trading period, 2seventy bio closed at $33.62.</li>
<li>With a Buy rating, Truist Securities initiated coverage on GitLab Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>). The price target seems to have been set at $175.00 for GitLab. At the end of the last trading period, GitLab closed at $123.54.</li>
<li>With an Overweight rating, Barclays initiated coverage on IHS Holding Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>). The price target seems to have been set at $24.00 for IHS Holding. IHS Holding earned $1.60 in the second quarter, compared to $1.50 in the year-ago quarter. Moreover, at the end of the last trading period, the closing price was at $16.32.</li>
<li>Wolfe Research initiated coverage on AvidXchange Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDX#NASDAQ">AVDX</a>) with an Outperform rating. The price target for AvidXchange Holdings is set to $31.00. At the end of the last trading period, AvidXchange Holdings closed at $23.81.</li>
<li>B of A Securities initiated coverage on GitLab Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) with a Buy rating. The price target for GitLab is set to $140.00. At the end of the last trading period, GitLab closed at $123.54.</li>
<li>With a Buy rating, B of A Securities initiated coverage on Latham Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>). The price target seems to have been set at $18.00 for Latham Group. Latham Group earned $0.49 in the second quarter. At the moment, the stock has a 52-week-high of $34.73 and a 52-week-low of $12.69. Latham Group closed at $16.05 at the end of the last trading period.</li>
<li>Goldman Sachs initiated coverage on IHS Holding Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHS#NYSE">IHS</a>) with a Buy rating. The price target for IHS Holding is set to $29.00. In the second quarter, IHS Holding showed an EPS of $1.60, compared to $1.50 from the year-ago quarter. Moreover, at the end of the last trading period, the closing price was at $16.32.</li>
</ul>
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings initiations.</a>

Upgrades

Downgrades

Initiation

Intraday Update

Analyst Ratings

ACEL

ACMR

AMTB

APPN

APTV

AVDX

BLUE

BTRS

CALA

CGNX

DCPH

DMTTF

DMYQ

DNUT

EARN

FICO

GTLB

ITRI

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

KVHI

LUCD

MCFE

MITT

NKTR

PALT

PLMR

PMCB

PRPL

ROIV

SHAK

SWIM

TILE

TSVT

Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2021

JP Morgan analyst Domingos Falavina upgrades Cielo (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CIOXY#OTC">CIOXY</a>) from Underweight to Neutral.

Comments

Cielo SA ADR

Cielo SA ADR (CIOXY) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル